Why Is Altimmune Stock Falling Today?

Altimmune (NASDAQ:ALT) shares are down during Thursday’s premarket session following the announcement of a $225 million public offering of securities. The stock’s decline comes as the company aims to fund its upcoming Phase 3 trial for its lead candidate, pemvidutide,...